This study was designed to explore the function of UBE4B in the development of lung adenocarcinoma (LUAD) and the role of PP2A/AKT in this process. Bioinformatics analysis, qRT-PCR, western blot, and immunohistochemistry were used to assess the gene expression in clinical samples, human LUAD database, human LUAD tissue microarrays, LUAD cells, and tumor xenograft model, respectively. The UBE4B overexpression and shRNA vector was constructed and transfected into LUAD cells, and the cell viability, migration, lactate production, and glycolysis were detected. The interaction between UBE4B and PP2A was assessed by CoIP and ubiquitination assay. The enhanced UBE4B expression is confirmed in LUAD datasets, clinical samples, human LUAD tissue microarrays and LUAD cells. UBE4B is positively associated with the proliferation, migration, lactate production, and glycolysis in LUAD cells, and UBE4B elevated proliferation, migration, lactate production, and glycolysis are abolished by PP2A overexpression. Mechanistically, UBE4B ubiquitinates PP2A and induces the activation of AKT. In conclusion, UBE4B act as an oncogene in the development of LUAD through PP2A/AKT signaling. UBE4B could be a new target for diagnosis and treatment of lung adenocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prp.2022.153762 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential gene expression in PBMCs: Insights into the mechanism how pulmonary tuberculosis increases lung cancer risk.
Gene
December 2024
Scientific Research Center, The Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China; Department of Clinical Laboratory, The Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China. Electronic address:
Pre-existing of pulmonary tuberculosis (PTB) poses increased lung cancer risk, yet the molecular mechanisms remain inadequately understood. This study sought to elucidate the potential mechanisms by performing comprehensive analyses of differentially expressed genes (DEGs) in peripheral blood mononuclear cells (PBMCs) from patients with PTB, lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC). Microarray assays were employed to analyze the DEGs in PBMCs of these patients.
View Article and Find Full Text PDFUnveiling chemotherapy-induced immune landscape remodeling and metabolic reprogramming in lung adenocarcinoma by scRNA-sequencing.
Elife
December 2024
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis.
View Article and Find Full Text PDFThe role of KRT18 in lung adenocarcinoma development: integrative bioinformatics and experimental validation.
Discov Oncol
December 2024
School of Pharmacy, Shaoyang University, Shaoyang, 422000, Hunan, China.
Lung adenocarcinoma (LUAD) represents one of the most common subtypes of lung cancer with high rates of incidence and mortality, which contributes to substantial health and economic demand across the globe. Treatment today mainly consists of surgery, radiotherapy, and chemotherapy, but their efficacy in advanced stages is often suboptimal and emphasizes the clear need for new biomarkers and therapeutic targets. Using comprehensive bioinformatics analyses consisting of the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Human Protein Atlas (HPA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC), immune infiltration analysis and functional enrichment analysis, and single-cell analysis, we examined the potential of keratin 18 (KRT18) as a candidate biomarker in advanced LUAD.
View Article and Find Full Text PDFSTIL Overexpression Is Associated with Chromosomal Numerical Abnormalities in Non-Small-Cell Lung Carcinoma Through Centrosome Amplification.
Curr Oncol
December 2024
Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
STIL is a regulatory protein essential for centriole biogenesis, and its dysregulation has been implicated in various diseases, including malignancies. However, its role in non-small-cell lung carcinoma (NSCLC) remains unclear. In this study, we examined STIL expression and its potential association with chromosomal numerical abnormalities (CNAs) in NSCLC using The Cancer Genome Atlas (TCGA) dataset, immunohistochemical analysis, and in vitro experiments with NSCLC cell lines designed to overexpress STIL.
View Article and Find Full Text PDF[High expression of SLC2A1 inhibits ferroptosis and promotes proliferation and invasion of lung adenocarcinoma cells].
Nan Fang Yi Ke Da Xue Xue Bao
December 2024
Department of Thoracic Surgery, First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
Objectives: To examine how the glucose transporter SLC2A1 influences the proliferation and migration of lung adenocarcinoma (LUAD) and explore the underlying molecular mechanisms.
Methods: We examined the differential expression of SLC2A1 between normal and LUAD tissues in the TCGA database and its prognostic implications. Immunohistochemistry was used to detect SLC2A1 protein levels in clinical samples of LUAD and adjacent tissues, and the association of SLC2A1 expression levels with clinicopathological features of the patients was analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!